333 related articles for article (PubMed ID: 21392266)
1. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides.
Rehfeld JF
Acta Physiol (Oxf); 2011 Apr; 201(4):405-11. PubMed ID: 21392266
[TBL] [Abstract][Full Text] [Related]
2. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
3. The biology of incretin hormones.
Drucker DJ
Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
[TBL] [Abstract][Full Text] [Related]
4. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
5. What do we know about the secretion and degradation of incretin hormones?
Deacon CF
Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
[TBL] [Abstract][Full Text] [Related]
6. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
7. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
8. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
Knop FK; Holst JJ; Vilsbøll T
IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
[TBL] [Abstract][Full Text] [Related]
9. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach.
Lippl F; Kircher F; Erdmann J; Allescher HD; Schusdziarra V
Regul Pept; 2004 Jun; 119(1-2):93-8. PubMed ID: 15093702
[TBL] [Abstract][Full Text] [Related]
10. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
11. Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B
Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044
[TBL] [Abstract][Full Text] [Related]
12. The role of incretin on diabetes mellitus.
Sanusi H
Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
[TBL] [Abstract][Full Text] [Related]
13. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
[TBL] [Abstract][Full Text] [Related]
14. CCK-1 and CCK-2 receptor agonism do not stimulate GLP-1 and neurotensin secretion in the isolated perfused rat small intestine or GLP-1 and PYY secretion in the rat colon.
Modvig IM; Christiansen CB; Rehfeld JF; Holst JJ; Veedfald S
Physiol Rep; 2020 Jan; 8(2):e14352. PubMed ID: 31984675
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA; Holst JJ; Willms B; Schmiegel W
Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
[TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes.
Pathak V; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():229-235. PubMed ID: 29412823
[TBL] [Abstract][Full Text] [Related]
17. Extrapancreatic effects of GIP and GLP-1.
Vella A; Rizza RA
Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
[TBL] [Abstract][Full Text] [Related]
18. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin.
Hardikar AA; Wang XY; Williams LJ; Kwok J; Wong R; Yao M; Tuch BE
Endocrinology; 2002 Sep; 143(9):3505-14. PubMed ID: 12193564
[TBL] [Abstract][Full Text] [Related]
19. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
20. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans.
Meier JJ; Holst JJ; Schmidt WE; Nauck MA
Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E849-56. PubMed ID: 17609256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]